This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ibrutinib, PCI-32765
PCI-32765 is a small molecule tyrosine kinase inhibitor. When immune cells called B-lymphocytes are overactive, the immune system produces inflammatory cells and antibodies that begin to attack the body's own tissue, leading to autoimmune diseases such as rheumatoid arthritis.
PCI-32765 is designed to inhibit a tyrosine kinase known as Bruton's tyrosine kinase (BTK), which is required for early B-cells to mature into fully functioning cells. In animal models, PCI-32765 has been hown to be effective in arthritis models and may inhibit the proliferation of lymphoma cells, a malignancy involving B-cells.
In addition to BTK, Ibrutinib has also been shown to inhibit interleukin-2-inducible kinase (ITK), a kinase that is highly expressed in T cells and is involved in T cell proliferation and differentiation (Blood 2013, 122:2539-2549).
Revenue splits are BioMedTracker estimates.
Pharmacyclics and Celera
In April 2006, Pharmacyclics acquired multiple small molecule drug candidates for the treatment of cancer and other diseases from Celera Genomics. Under the terms of the agreement, Pharmacyclics has acquired Celera technology and intellectual property relating to drugs that target histone deacetylase (HDAC) enzymes, selective HDAC enzymes, angiogenesis molecules and B cell tyrosine kinases involved in immune function.
The financial terms of the transaction include an upfront cash payment of $2 million and an equity payment of between five hundred thousand and one million shares of Pharmacyclics common stock, depending on Pharmacyclics' stock price during a specified period. If these programs meet certain developmental stage milestone events and result in drugs that are approved and commercialized in key geographical markets they may generate potential future milestone payments to...See full deal structure in Biomedtracker
Partners: Johnson & Johnson Royalty Pharma AG
Additional information available to subscribers only: